For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.
Even though the EMBRACE study adds to the literature, according to authors the “best way” to screen men with germline DNA damage repair abnormalities “remains unclear.”
A post-hoc analysis of a phase 3 trial demonstrated that adding 6 months of androgen deprivation therapy to salvage radiotherapy for recurrent prostate cancer following radical prostatectomy improves progression-free survival at 120 months.
In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
Researchers sought to determine if practicing Kegel exercises, a common pelvic-floor exercise, could prevent urinary and fecal incontinence in patients with prostate cancer.
Men who receive first-line abiraterone or enzalutamide or first-line docetaxel treatment for metastatic castration-resistant prostate cancer have similar overall survival, a prospective, observational cohort study found.
In a phase 3 trial of men with metastatic castration-resistant prostate cancer and altered DNA repair genes, olaparib-treated patients had significantly longer radiographic progression-free survival compared with enzalutamide or abiraterone recipients.
In a study, fathers who used intra-cytoplasmic sperm injection or in vitro fertilization had higher risk for prostate cancer than men who conceived naturally.
Men with the BRCA1 and BRCA2 mutation have absolute lifetime risks for developing prostate cancer of 29% and 60%, respectively, according to investigators.
